1 / 138

New Drugs of 2007 Part 3

New Drugs of 2007 Part 3. Presented by: Sarah Rodriguez, PharmD Drugs Covered: azithromycin (Azasite ® ) doripenem (Doribax ™ ) raltegravir (Isentress ™ ) maraviroc (Selzentry ™ ) temsirolimus (Torisel ™ ). Azithromycin. Azasite ®.

graceland
Download Presentation

New Drugs of 2007 Part 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. New Drugs of 2007 Part 3 Presented by: Sarah Rodriguez, PharmD Drugs Covered: azithromycin (Azasite®) doripenem (Doribax™) raltegravir (Isentress™) maraviroc (Selzentry™) temsirolimus (Torisel™)

  2. Azithromycin Azasite® Manufactured by: Inspire www.prescribingreference.com

  3. Azithromycin (Azasite®) Therapeutic Class • Ophthalmic antimicrobial Indications • Treatment of bacterial conjunctivitis caused by • Haemophiliusinfluenzae • Staphylococcus aureus • Streptococcus mitis • Streptococcus pneumoniae • CDC coryneform group G Azasite® (Azithromycin) package insert. Durham, NC: Inspire. May 2007.

  4. Mechanism of action Interferes with bacterial protein synthesis by binding to the 50S ribosomal subunit Pharmacokinetics Systemic absorption is minimal Azithromycin (Azasite®) Azasite® (Azithromycin) package insert. Durham, NC: Inspire. May 2007.

  5. Azithromycin (Azasite®) Dosing and Administration • 1 drop in the affected eye(s) twice daily for two days, then 1 drop daily for five days Cost • $66.25/bottle(AWP) Azasite® (Azithromycin) package insert. Durham, NC: Inspire. May 2007.

  6. Azithromycin (Azasite®) Contraindications & Precautions • No contraindications • Severe allergic reactions have been seen with systemic use of azithromycin • Long-term use can result in resistant infections developing Drug Interactions • None identified Adverse Effects • Eye irritation most common Azasite® (Azithromycin) package insert. Durham, NC: Inspire. May 2007.

  7. Azithromycin (Azasite®) Azasite® (Azithromycin) package insert. Durham, NC: Inspire. May 2007.

  8. Azithromycin (Azasite®) Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 Safety Comparisons for 1.0% Azithromycin Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye drops for Bacterial Conjunctivitis. Invest Ophthalmol Vis Sci. @007;48:3425-3429.

  9. Azithromycin (Azasite®) Patient Education • Wash hands before using • Avoid touching the tip of the bottle to the eye • Important to complete full course of therapy • Do not wear contact lenses

  10. Azithromycin (Azasite®) Place in Therapy • Less frequent dosing than other available treatments for bacterial conjunctivitis Clinical Pearls • Offers no therapeutic advantage over currently available products

  11. Question 1 Which of the following is an advantage of azithromycin (Azasite®) over other treatments for bacterial conjunctivitis?

  12. 15 Answer now! • It is much more efficacious than other available agents • Systemic absorption allows for eradication of the causative bacteria elsewhere in the body • It requires less frequent dosing than other available agents • It can be used in infants less than one year of age

  13. Question 2 A doctor calls the pharmacy wishing to prescribe azithromycin (Azasite) for bacterial conjunctivitis. This agent is currently non-formulary at your institution. Which of the following agents would be a valid therapeutic alternative?

  14. 15 Answer now! • Meropenem • Gentamicin • Prednisolone • Ceftazidime

  15. Doripenem Doribax™ Manufactured by: Ortho-McNeil www.prescribingreference.com

  16. Doripenem (Doribax™) Therapeutic Class • Carbapenem antibiotic Indications • Complicated intra-abdominal infections • Complicated urinary tract infections, including pyelonephritis Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  17. Mechanism of action Binds to penicillin binding proteins Inhibits synthesis of bacterial cell wall Bacteriocidal Pharmacokinetics Distribution: 8% protein bound Concentrates in peritoneal fluid, retroperitoneal fluid, gallbladder, bile, and urine Metabolism: Metabolized to an inactive, open ring form by dehydropeptidase-1 Not a substrate for CYP450 Elimination: Renal Half-life is 1 hour Doripenem (Doribax™) Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  18. Doripenem (Doribax™) Dosing and Administration • Complicated intra-abdominal infections • 500 mg infused over 1 hour every 8 hours for 5 – 14 days • Complicated urinary tract infections • 500 mg infused over 1 hour every 8 hours for 10 days Cost • $95.83/dose (AWP) Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  19. Doripenem (Doribax™) Contraindications & Precautions • Severe hypersensitivity reactions have occurred • Clostridium difficile associated diarrhea • Overuse can result in development of drug-resistant bacteria • Cases of pneumonitis reported with inhalational use Drug Interactions • Valproic acid • Probenecid Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  20. Doripenem (Doribax™) Adverse Reactions • Headache • Nausea • Diarrhea • Rash • Phlebitis • Seizure Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  21. Doripenem (Doribax™) Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  22. Doripenem (Doribax™) Doripenem (Doribax®) Package Insert. Raritan, NJ: Ortho-McNeal. October, 2007.

  23. Doripenem (Doribax™) Patient Education • Possibility of severe allergic reactions • Only used for the treatment of bacterial infections • Full course of therapy should be completed

  24. Doripenem (Doribax™) Place in Therapy: • Broad spectrum antibiotic • Reserve for patients at high risk for serious, multi-drug resistant infections • Effective against Pseudomonas aeruginosa and may be more potent in its activity than other carbapenems • No indication for Pseudomonal infections at this time Clinical Pearls: • Superiority over other carbapenems not established • Pneumonia indication currently under review • Will require 4 hour infusion Zhanel GG, Wiebe R, Dilay L, et al. Comparative Review of the Carbapenems. Drugs 2007;67(7):1027 – 1052. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of Carbapenems for the Prevention of Carbapenem- Resistant Mutants of Pseudomonas aeruginosa. J Antibiot 2006;59(4): 220-228.

  25. Question 3 Which of the following drugs has the same mechanism of action as doripenem?

  26. 15 Answer now! • Gentamicin • Colistin • Ceftriaxone • Tigecycline

  27. Question 4 Which of the following nosocomial pathogens does doripenem have activity against?

  28. 15 Answer now! • Pseudomonas aeruginosa • Methicillin resistant Staphylococcus aureus • Vancomycin Resistant Enterococcus faecalis • Clostridium difficile

  29. Life Cycle of HIV: Therapeutic Targets http://img.thebody.com/

  30. Raltegravir Isentress™ Manufactured by: Merck www.prescribingreference.com

  31. Raltegravir (Isentress™) Therapeutic Class • HIV integrase inhibitor Indications • Treatment of HIV-1 infection • Only used in combination with other agents • Patients with evidence of multi-drug resistance Isentress (Raltegravir®) Package insert. Merck and Company, Whitehouse Station, NJ. October, 2007.

  32. Mechanism of action Inhibits HIV-1 integrase Pharmacokinetics Absorption: Bioavailability not known AUC is increased by 19% with a high-fat meal Distribution: 83% protein bound Metabolism: Glucuronidated by UGT1A1 Elimination: 51% of the dose is excreted in the feces 32% in the urine Half-life 9 hours Raltegravir (Isentress™) Isentress (Raltegravir®) Package insert. Merck and Company, Whitehouse Station, NJ. October, 2007.

  33. Raltegravir (Isentress™) Dosing and Administration • 400 mg twice daily with or without food Cost • $1,012.50/month(AWP) Contraindications & Precautions • No contraindications • Immune reconstitution syndrome to residual opportunistic infections • Pregnancy category C Isentress (Raltegravir®) Package insert. Merck and Company, Whitehouse Station, NJ. October, 2007.

  34. Raltegravir (Isentress™) Drug Interactions • Use caution in giving raltegravir with strong inducers of UGT1A1 • Rifampin can decrease plasma concentrations of raltegravir through UGT1A1 induction • Tipranavir, ritonavir, and atazanavir also affect UGT1A1, but dose adjustment does not appear to be needed • Increased risk of rhabdomyolysis with concurrent use of statins and fibrates Isentress (Raltegravir®) Package insert. Merck and Company, Whitehouse Station, NJ. October, 2007.

  35. Raltegravir (Isentress™) Adverse Effects • Most Common • Diarrhea • Nausea • Headache • Fever • Myopathy • Elevated liver enzymes • Especially in those co-infected with Hepatitis B or C Isentress (Raltegravir®) Package insert. Merck and Company, Whitehouse Station, NJ. October, 2007.

  36. Raltegravir (Isentress™) Jones, J, Taylor B, Wilkin TJ, Hammer SM. Advances in Antiretroviral Therapy. Top HIV Med 2007;15(2)48:82.

  37. Raltegravir (Isentress™) Patient Education • Not a cure for HIV • Importance of compliance with antiretroviral regimens • Report any unusual muscle pain or weakness

  38. Raltegravir (Isentress™) Place in Therapy: • Novel mechanism of action shown to be efficacious even in patients with very resistant HIV infections • Studies ongoing in treatment naïve patients • Low pill burden Clinical Pearls: • May be particularly effective when given in combination with darunavir and enfuvirtide Jones, J, Taylor B, Wilkin TJ, Hammer SM. Advances in Antiretroviral Therapy. Top HIV Med 2007;15(2)48:82. Correll T, Klibanov OM. Integrase Inhibitors: A New Treatment Option for Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy 2008, 28(1):91 – 100.

  39. Question 5 Which of the following co-morbidities in an HIV positive patient may increase the likelihood of toxicity when treated with raltegravir?

  40. 15 Answer now! • Hepatitis C • Diabetes mellitus • Chronic renal insufficiency • Kaposi’s sarcoma

  41. Question 6 A patient in your unit comes in with new onset of shingles. Upon reviewing his history, you find that he is HIV positive and recently underwent a change in his antiretroviral medications. His physician wants to discontinue the new therapy since it is not working. What is your advice?

  42. 20 Answer now! • Agree with the MD and discontinue all antiretroviral therapy immediately • Discontinue all of his antiretroviral agents but one to keep his HIV under control until you figure out what his new regimen will be • Advise the MD to continue the patient’s current therapy and add on raltegravir to maintain better control of his HIV • Advise the MD that the patient just had a change in his antiretroviral medications and his symptoms may be due to immune reconstitution syndrome

  43. Maraviroc Selzentry™ Manufactured by: Pfizer www.prescribingreference.com

  44. Maraviroc (Selzentry™) Therapeutic Class • CCR5 co-receptor antagonist Indications • Treatment of CCR5-tropic HIV-1 infection • Only in combination with other antiretroviral agents • Treatment experienced patients who have evidence of multi-drug resistance Selzentry® (Maraviroc) Package Insert. Pfizer Labs, New York, NY. August, 2007.

  45. Mechanism of action Antagonizes the interaction between CCR5 and HIV gp120 Prevents HIV from entering the cell Pharmacokinetics Absorption: Low bioavailability AUC is decreased by high-fat meal Maraviroc is also a substrate for P-glycoprotein Distribution: 76% protein bound Metabolism: CYP450 3A4 substrate Elimination: 76% of the dose is excreted in the feces 20% in the urine Half-life of 18 hours Maraviroc (Selzentry™) Selzentry® (Maraviroc) Package Insert. Pfizer Labs, New York, NY. August, 2007.

  46. Maraviroc (Selzentry™) Cost • $1087.50/bottle(AWP) • Does not differ with strength Selzentry® (Maraviroc) Package Insert. Pfizer Labs, New York, NY. August, 2007.

  47. Maraviroc (Selzentry™) Contraindications & Precautions • Black box warning for hepatotoxicity • Preceded by allergic symptoms including rash, eosinophilia, and elevated IgE • Discontinue immediately if patient develops symptoms of hepatitis or elevated liver enzymes • Little data in patients with Hepatitis B, Hepatitis C, or other forms of liver impairment • Cardiovascular events including myocardial infarction and ischemia • Immune reconstitution syndrome to residual opportunistic infections • Increased risk of infection • Increased risk of malignancy Selzentry® (Maraviroc) Package Insert. Pfizer Labs, New York, NY. August, 2007.

  48. Maraviroc (Selzentry™) Drug Interactions • Caution in patients with a history of postural hypotension or in those receiving anti-hypertensive medications due to increased risk of symptomatic hypotension • CYP3A4 inducers and inhibitors Adverse Effects • Cough • Fever • Upper respiratory tract infections • Rash • Musculoskeletal pain • Abdominal pain • Dizziness • Hepatotoxicity, especially in patients with pre-existing hepatic dysfunction Selzentry® (Maraviroc) Package Insert. Pfizer Labs, New York, NY. August, 2007.

  49. Maraviroc (Selzentry™) Jones, J, Taylor B, Wilkin TJ, Hammer SM. Advances in Antiretroviral Therapy. Top HIV Med 2007;15(2)48:82.

  50. Maraviroc (Selzentry™) Patient Education • Not a cure for HIV • Importance of compliance with antiretroviral regimens • Notify physician immediately if symptoms of hepatitis develop such as yellowing of the skin or eyes, abdominal pain, dark urine, or vomiting

More Related